Corden Pharma SpA

Today, a brief rundown of news from Caribou Sciences and Relay Therapeutics as well as updates from Corden Pharma, Celldex Therapeutics, and Beam Therapeutics that you may have missed.Caribou Biosciences is laying off staff one month after a clinical setback sent its shares tumbling. In a regulatory filing Tuesday, the company said it has reduced its workforce by 12%, or by 21 positions. Caribou also has discontinued preclinical research on its allogeneic CAR-NK platform. Together, the moves will extend the companys cash runway and focus resources on its CAR-T therapies, data for one of which it presented last month. Delilah AlvaradoRoche is walking away from a cancer drug collaboration with Relay Therapeutics that it struck in 2020. Relay disclosed in a filing Tuesday that Roche elected to terminate the partnership, which centered on an experimental SHP2 inhibitor the companies sought to pair with KRAS-blocking medicines. Relay had received $75 million upfront from Roche and stood to gain hundreds of millions of dollars more in milestone payments if the collaboration had succeeded. Delilah AlvaradoCordenPharma, a contract development and manufacturing organization, will invest about 900 million euros($984 million) over the next three years to expand its capacity to make peptide-based drugs in the U.S. and Europe. The spending plans, which are CordenPharmas largest strategic investment to date, are designed to position the company to meet rising demand for producing GLP-1 medicines, like those now used to treat diabetes and obesity. Ned PagliaruloCelldex Therapeutics has begun two Phase 3 trials testing its experimental drug barzolvolimab in adults with chronic spontaneous urticaria, or hives. The studies are set to enroll more than 1,800 people who continue to have symptoms despite treatment with antihistamines. Celldexs drug, which showed potential in mid-stage testing, targets a protein thought to control the immune cells that can cause skin swelling and inflammation. Ned PagliaruloTerry-Ann Burrell, the chief financial officer of Beam Therapeutics for the past five years, is leaving the gene editing company next month to return to JPMorgan Chase, where shell be the vice chairman of investment banking. During her time as Beams CFO, she helped the company raise nearly $500 million via an initial public offering and a subsequent private placement. Beam has begun a search for her successor. Ned Pagliarulo '

Corden Pharma is investing $1bn to increase its European and US manufacturing capacities for diabetes therapies. Credit: EXTREME-PHOTOGRAPHER via Getty Images. German contract development and manufacturing organisation (CDMO) Corden Pharma announced a €900m ($980m) investment to expand its diabetes drug manufacturing capabilities , as shortages persist around the world. The company declared that the investment would be used over the next three years to expand its peptide manufacturing capabilities at sites in Colorado, US, and Europe. The facilities will have a particular focus on GLP-1 peptide manufacturing, as the demand increases. In a 16 July press release, the company spoke of multiple long-term contracts worth more than €3bn with potential benefits. Last year, the company signed a major deal with Eli Lilly to manufacture the active pharmaceutical ingredient for its leading obesity drug Mounjaro (tirzepatide), as per a Reuters report. In January 2023, the company also shared the signing of a $1bn multi-year agreement to manufacture a large volume peptide with an undisclosed company. The latest investment will be used to construct a greenfield site for large-scale peptide manufacturing. These plans, alongside previous expansions made this year, aim to help Corden achieve its $1bn 2028 sales target. Other companies such as Aurisco Pharmaceutical and Novo Nordisk have also made major investments in their peptide manufacturing plants to meet the growing demand for GLP-1 receptor agonists. Over the years, GLP-1 receptor agonist therapies have taken over the diabetes and weight loss fields, delivering significant financial success for several companies. Novo Nordisk ’s type 2 diabetes therapy Ozempic (semaglutide) earned the company approximately $14bn in global sales last year while Eli Lilly’s Mounjaro (tirzepatide) amassed $5.16bn in global sales in 2023. GlobalData’s consensus forecasts predict that global sales for the therapies could reach $22.43bn and $27.42bn in 2030 respectively. See Also: Explainer: Labour has been elected in the UK – now what? GlobalData is the parent company of Pharmaceutical Technology. “Despite our collective efforts the [GLP-1 receptor agonist] shortages continue and there are no instant solutions, and we don’t expect them to be resolved this year,” said Emer Cooke, the European Medicines Agency’s (EMA) executive director, in a 26 June statement. Due to this, the agency released actions to tackle the shortage, asking EU member states to work with drug manufacturers to control and improve the distribution of the drugs. The agency has also planned a real-world data study, with Darwin EU, to assess how the medicines are being used in real life. The EMA’s Medicine Shortages Single Point of Contact Working Party also advised companies to increase their manufacturing capacities and implement awareness campaigns for the therapies. Other major organisations such as the World Health Organization (WHO) and the US Food and Drug Administration have also spoken out against the supply shortages. Amid the supply issues, WHO warned patients to stay away from falsified GLP-1RA products .

DUBLIN, July 14, 2022 /PRNewswire/ -- The "Global Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Tablets, Capsules), by Mechanism (Controlled-, Immediate-release), by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global oral solid dosage contract manufacturing market size is expected to reach USD 54.7 billion by 2030, registering a CAGR of 6.0% over the forecast period. Increasing complexity of new drug molecules, R&D investments by large Contract Manufacturing Organizations (CMOs) & Contract Development & Manufacturing Organization (CDMOs), and rising demand for new therapies would drive the growth of the market. Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as the delivery of drugs and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency. The global market is growing in conjunction with the oncology sector. Clinical-stage cancer programs increased by 77% between 2015 and 2020 (1,642 to 2,911) and completely dominate the landscape, resulting in approximately one-quarter of drugs currently being developed globally being classified as highly potent. This tendency forward into high potency is having a significant impact on the CDMO space, as the increasing demand for smaller-scale and encapsulated manufacturing processes presents a challenge for most of pharma's installed capacity. The COVID-19 crisis has had a number of short- and long-term consequences. The healthcare sector witnessed a considerable decline in its revenue recognition during the year 2020 due to labor shortages and disruption of the raw material supply chain. However, drug sponsors are focusing on enhancing their efforts in the R&D of drug products that will help treat viral infection. Moreover, small molecule oral solid dosage (OSD) products, such as azithromycin and hydroxychloroquine, etc. have a positive impact on the COVID-19-infected population. Hence, an increasing number of manufacturers were focused on the commercialization and production of such OSD drug products, thus supporting the market growth. Moreover, the industry witnessed a significant surge in 2020 and 2021, as a new and high number of CMOs were allocated with contracts of OSD as a potential treatment of the COVID-19 infection. For instance, in August 2020, Pfizer Inc. announced an agreement with Gilead Sciences, Inc. to provide contract manufacturing services for the supply and manufacturing of Gilead's investigational antiviral remdesivir drug, with an aim to scale up the supply of the investigational treatment for COVID-19 patients. Hence, such factors are supporting the demand surge of OSD products across 2020 and 2021. Oral Solid Dosage Contract Manufacturing Market Report Highlights The tablets segment dominated the market in 2021. Tablets are the most common OSD forms. It is the most popular dosage due to its compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing drive the market growth. Based on end-user, the large-size companies segment accounted for the largest revenue share in 2021. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability. As more pharma developers design drugs from the start with the intention of outsourcing them to large CMOs, it's only natural that large CMOs gain more leverage in the development pipeline. Asia Pacific led the global market in 2021 and is projected to witness the fastest CAGR during the forecast years as China and India are the powerhouses of OSD CMO with significantly lower prices. Key Topics Covered: Chapter 1 Methodology and Scope Chapter 2 Executive Summary Chapter 3 Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope 3.1 Market Segmentation and Scope 3.2 Market Dynamics 3.2.1 Market Driver Analysis 3.2.1.1 Technological advancements in oral solid dosage forms 3.2.1.2 Increasing demand for the novel therapies 3.2.1.3 R&D Investments by CMOs & CDMOs 3.2.2 Market Restraint Analysis 3.2.2.1 Strict Approval Criteria by Regulatory Authorities 3.2.2.2 Less availability of experienced technical staff, as well as physical capability and capacity of the equipment. 3.2.2.3 Rising research on biologic molecules and their dominance in treating oncology conditions 3.3 Penetration & Growth Prospect Mapping 3.4 COVID-19 Impact on the Market 3.5 Major Deals and Strategic Alliances Analysis 3.6: Market Analysis Tools 3.6.1 Industry Analysis-Porter's 3.6.2 PESTEL Analysis Chapter 4 Oral Solid Dosage Contract Manufacturing Market: Product Type Segment Analysis 4.1 Oral Solid Dosage Contract Manufacturing Market: Definition & Scope 4.2 Oral Solid Dosage Contract Manufacturing Market: Market Share Analysis, 2021 & 2030 4.3 Tablets 4.3.1 Tablets Market, 2018-2030 (USD Million) 4.4 Capsules 4.4.1 Capsules Market, 2018-2030 (USD Million) 4.5 Powders 4.5.1 Powders Market, 2018-2030 (USD Million) 4.6 Granules 4.6.1 Granules Market, 2018-2030 (USD Million) 4.7 Others 4.7.1 Others Market, 2018-2030 (USD Million) Chapter 5 Oral Solid Dosage Contract Manufacturing Market: Mechanism Analysis 5.1 Oral Solid Dosage Contract Manufacturing Market: Definition & Scope 5.2 Oral Solid Dosage Contract Manufacturing Market : Market Share Analysis, 2021 & 2030 5.3 Immediate Release 5.3.1 Immediate Release Market, 2018-2030 (USD Million) 5.4. Delayed Release 5.4.1 Delayed Release Market, 2018-2030 (USD Million) 5.5 Controlled Release 5.5.1. Controlled Release Market, 2018-2030 (USD Million) Chapter 6 Oral Solid Dosage Contract Manufacturing Market: End-user Analysis 6.1 Oral Solid Dosage Contract Manufacturing Market: Definition & Scope 6.2 Oral Solid Dosage Contract Manufacturing: Market Share Analysis, 2021 & 2030 6.3 Large Size Companies 6.3.1 Large Size Companies Market, 2018-2030 (USD Million) 6.4. Medium & Small Size Companies 6.4.1 Medium & Small Size Companies Market, 2018-2030 (USD Million) 6.5 Others 6.5.1. Others Market, 2018-2030 (USD Million) Chapter 7 Oral Solid Dosage Contract Manufacturing Market: Regional Analysis Chapter 8 Company Profiles 8.1 Company Profiles 8.1.1 Catalent 8.1.1.1 Company overview 8.1.1.2 Financial performance 8.1.1.3 Service benchmarking 8.1.1.4 Strategic initiative 8.1.2 Lonza Group 8.1.2.1 Company overview 8.1.2.2 Financial performance 8.1.2.3 Service benchmarking 8.1.3.4 Strategic initiatives 8.1.3 Piramal Pharma Solutions 8.1.3.1 Company overview 8.1.3.2 Financial performance 8.1.3.3 Service benchmarking 8.1.3.4 Strategic initiatives 8.1.4 Aenova 8.1.4.1 Company overview 8.1.4.2 Financial performance 8.1.4.3 Product benchmarking 8.1.4.4 Strategic initiatives 8.1.5 Boehringer Ingelheim 8.1.5.1 Company overview 8.1.5.2 Product benchmarking 8.1.5.3 Strategic initiatives 8.1.6 AbbVie Contract Manufacturing 8.1.6.1 Company overview 8.1.6.2 Product benchmarking 8.1.6.3 Strategic initiatives 8.1.7 Jubilant 8.1.7.1 Company overview 8.1.7.2 Financial performance 8.1.7.3 Product benchmarking 8.1.7.4 Strategic initiatives 8.1.8 Patheon 8.1.8.1 Company overview 8.1.8.2 Financial performance 8.1.8.3 Product benchmarking 8.1.9 Recipharm 8.1.9.1 Company overview 8.1.9.2 Financial performance 8.1.9.3 Product benchmarking 8.1.10 Next Pharma AB 8.1.10.1 Company overview 8.1.10.2 Financial performance 8.1.10.3 Product benchmarking 8.1.10.4 Strategic Initiatives 8.1.11 Corden Pharma 8.1.11.1 Company overview 8.1.11.2 Financial performance 8.1.11.3 Product benchmarking 8.1.11.4 Strategic Initiatives 8.1.12 Siegfried AG 8.1.12.1 Company overview 8.1.12.2 Financial performance 8.1.12.3 Product benchmarking 8.1.12.4 Strategic Initiative For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets